Sionna Therapeutics (NASDAQ:SION) Upgraded at Lifesci Capital

Lifesci Capital upgraded shares of Sionna Therapeutics (NASDAQ:SION) to a strong-buy rating in a report issued on Wednesday morning,Zacks.com reports.

Other equities research analysts also recently issued reports about the company. BTIG Research restated a “buy” rating and issued a $58.00 target price on shares of Sionna Therapeutics in a research report on Wednesday, January 14th. Wall Street Zen upgraded Sionna Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sionna Therapeutics in a research note on Monday, December 29th. Raymond James Financial reiterated a “strong-buy” rating and issued a $53.00 price target on shares of Sionna Therapeutics in a research report on Monday, January 5th. Finally, Citigroup started coverage on shares of Sionna Therapeutics in a research report on Tuesday. They set an “outperform” rating for the company. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat, Sionna Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $47.63.

Sionna Therapeutics Stock Performance

Shares of SION opened at $36.54 on Wednesday. The firm has a market capitalization of $1.63 billion and a price-to-earnings ratio of -7.50. Sionna Therapeutics has a one year low of $7.26 and a one year high of $45.00. The stock’s fifty day moving average is $39.78 and its 200-day moving average is $34.93.

Insiders Place Their Bets

In other Sionna Therapeutics news, major shareholder Tpg Gp A, Llc sold 250,000 shares of the company’s stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $40.00, for a total transaction of $10,000,000.00. Following the completion of the sale, the insider directly owned 6,494,962 shares of the company’s stock, valued at approximately $259,798,480. This represents a 3.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Peter A. Thompson sold 29,063 shares of Sionna Therapeutics stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $44.58, for a total transaction of $1,295,628.54. Following the completion of the transaction, the director directly owned 3,530,702 shares in the company, valued at approximately $157,398,695.16. This trade represents a 0.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 382,368 shares of company stock worth $15,898,607. Company insiders own 3.90% of the company’s stock.

Institutional Trading of Sionna Therapeutics

A number of hedge funds have recently modified their holdings of SION. Braidwell LP purchased a new position in shares of Sionna Therapeutics during the second quarter valued at $18,770,000. Eventide Asset Management LLC purchased a new position in Sionna Therapeutics during the 4th quarter valued at about $26,290,000. Vanguard Group Inc. increased its holdings in shares of Sionna Therapeutics by 81.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,143,154 shares of the company’s stock valued at $33,620,000 after purchasing an additional 512,803 shares during the period. State Street Corp lifted its position in shares of Sionna Therapeutics by 188.7% in the fourth quarter. State Street Corp now owns 693,395 shares of the company’s stock worth $28,526,000 after purchasing an additional 453,196 shares in the last quarter. Finally, Viking Global Investors LP boosted its holdings in shares of Sionna Therapeutics by 8.2% during the second quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock worth $55,436,000 after purchasing an additional 242,427 shares during the period.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.